Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease (original) (raw)

Plasma α-synuclein in patients with Parkinson's disease with and without treatment

Manuel Ramirez

Movement Disorders, 2010

View PDFchevron_right

Alteration in α-synuclein mRNA expression in Parkinson's disease

Oliver Foster

Movement Disorders, 2004

View PDFchevron_right

Metabolic alterations in plasma from patients with familial and idiopathic Parkinson’s disease

Adolfo López de Munain

Aging, 2020

View PDFchevron_right

Alpha-synuclein, lipids and Parkinson’s disease

Violeta Ruipérez

Progress in Lipid Research, 2010

View PDFchevron_right

The native form of α-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls

Michael Jakowec

Neuroscience Letters, 1998

View PDFchevron_right

Parkinson’s disease and multiple system atrophy have distinct α-synuclein seed characteristics

Gabriel Teku

Journal of Biological Chemistry, 2018

View PDFchevron_right

Peroxidase Mechanism of Lipid-dependent Cross-linking of Synuclein with Cytochrome c: PROTECTION AGAINST APOPTOSIS VERSUS DELAYED OXIDATIVE STRESS IN PARKINSON DISEASE

Natalia Belikova

Journal of Biological Chemistry, 2009

View PDFchevron_right

Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein

Howard Federoff

2013

View PDFchevron_right

Synuclein activates microglia in a model of Parkinson's disease

Howard Federoff

Neurobiology of Aging, 2008

View PDFchevron_right

Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease

Dennis Dickson

Acta Neuropathologica, 2000

View PDFchevron_right

Dietary Intake of Parkinson's Disease Patients

Geertrui Vlaemynck

Frontiers in Nutrition, 2020

View PDFchevron_right

The Search for a Peripheral Biopsy Indicator of α-Synuclein Pathology for Parkinson Disease

David G Munoz

Journal of Neuropathology and Experimental Neurology, 2017

View PDFchevron_right

Oxidative Stress and Aminopeptidases in Parkinson’s Disease Patients with and without Treatment

Manuel Ramirez

Neurodegenerative Diseases, 2011

View PDFchevron_right

Inflammasome and α-synuclein in Parkinson's disease: A cross-sectional study

Akash Roy

Journal of Neuroimmunology, 2019

View PDFchevron_right

The Reaction of -Synuclein with Tyrosinase: POSSIBLE IMPLICATIONS FOR PARKINSON DISEASE

Marco Bisaglia

Journal of Biological Chemistry, 2008

View PDFchevron_right

Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models

Neil Cashman

Communications biology, 2021

View PDFchevron_right

Inflammation in Parkinson's Disease: Therapeutic Implications

Giuseppe Di Giovanni

2007

View PDFchevron_right

Deficits in a tricarboxylic acid cycle enzyme in brains from patients with Parkinson’s disease

Oliver Foster

Neurochemistry International, 2003

View PDFchevron_right

Parkinson Disease

Arthur Friedlander

The Journal of the American Dental Association, 2009

View PDFchevron_right

Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease

Gerda Andringa

The FASEB Journal, 2004

View PDFchevron_right

Possible causes of Parkinson’s disease

James D Adams

Frontiers in Bioscience-Landmark, 2021

View PDFchevron_right

Brain Network Metabolic Changes in Patients with Parkinsonian Tremors

David Eidelberg

InTech eBooks, 2016

View PDFchevron_right

Plasma lipid peroxidation in sporadic Parkinson's disease. Role of the l-dopa

Manuel Ramirez

Journal of the Neurological Sciences, 2006

View PDFchevron_right

Editorial: The Role of Lipids in the Pathogenesis of Parkinson's Disease

Gerard Martens

Frontiers in Neuroscience, 2020

View PDFchevron_right

Symptoms Affecting Food Intake and the Risk of Malnutrition in People with Parkinson S Disease

Julie Sørbø Helliesen, Asta Bye

Universitetet i Oslo, 2020

View PDFchevron_right

A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease

J. Arturo Garcia

British Journal of Pharmacology, 2012

View PDFchevron_right

The role of lipids in the central nervous system and their pathological implications in amyotrophic lateral sclerosis

Siobhán Kirk

Seminars in Cell & Developmental Biology, 2021

View PDFchevron_right

Inflammation and α-Synuclein’s Prion-like Behavior in Parkinson's Disease—Is There a Link?

Trevor Tyson

Molecular Neurobiology, 2013

View PDFchevron_right

Microglia, Amyloid, and Glucose Metabolism in Parkinson's Disease with and without Dementia

Zuzana Walker

Neuropsychopharmacology, 2013

View PDFchevron_right

Risk and sub phenotype in Parkinson’s disease

Reem amin

Journal of Neurology, 2013

View PDFchevron_right

α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy?

Tamas Revesz

Acta Neuropathologica, 2013

View PDFchevron_right

Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease

T. Gasalla

Journal of the Neurological Sciences, 1997

View PDFchevron_right

Supplement 4: Canadian Guidelines on Parkinson's Disease

Hrishikesh Kumar

The Canadian Journal of Neurological Sciences, 2012

View PDFchevron_right

Somatostatin and dementia in Parkinson's disease

Jacques Epelbaum

Brain Research, 1983

View PDFchevron_right

Nitrated alpha-synuclein-activated microglial profiling for Parkinson’s disease

Anathbandhu Chaudhuri

Journal of Neurochemistry, 2007

View PDFchevron_right